Vancouver, British Columbia--(Newsfile Corp. - December 18, 2025) - Legend Power Systems Inc. (TSXV: LPS) (OTCQB: LPSIF) ("Legend Power" or the "Company"), announces a non-brokered private placement of a minimum of 11,111,111 units and up to a maximum of 14,186,000 units of the Company (each, a "Unit") at a price of CAD$0.12 per Unit for aggregate gross proceeds of a minimum of CAD$1,333,333 and up to a maximum of CAD$1,702,320 (the "Offering"). The Offering is being completed pursuant to the amendments to ...

Core Insights - Viatris Inc. has announced four significant regulatory milestones in its global pipeline, highlighting advancements in research and development throughout 2025 [1][6][14] Group 1: Regulatory Approvals - The U.S. FDA has approved the company's octreotide acetate for injectable suspension, a generic version of Sandostatin LAR Depot, for treating acromegaly and certain cancer-related symptoms [6][14] - This approval marks the fourth injectable FDA approval for Viatris in 2025, alongside iron sucrose, paclitaxel, and liposomal amphotericin B, showcasing the company's ability to navigate complex regulatory pathways [3][14] - The FDA has accepted the New Drug Application (NDA) for a low dose estrogen weekly patch for contraception, with a target action date of July 30, 2026 [6][14] Group 2: Pipeline Developments - The investigational low dose estrogen weekly patch is designed for women with a BMI below 30 kg/m², delivering approximately 150 mcg of norelgestromin and 17.5 mcg of ethinyl estradiol per day [4][7] - The planned 505(b)(2) NDA for the patch is supported by positive results from the Phase 3 Luminous Study, demonstrating a favorable efficacy and safety profile [5][14] - The U.S. FDA has cleared the Investigational New Drug (IND) application for MR-146, a gene therapy candidate for neurotrophic keratopathy, with plans to initiate a Phase 1/2 clinical trial in the first half of 2026 [6][9][14] Group 3: International Developments - The Japan Pharmaceuticals and Medical Devices Agency has accepted the Japanese New Drug Application (J-NDA) for pitolisant in obstructive sleep apnea syndrome, supported by positive Phase 3 data [6][11][14] - The Phase 3 trial for pitolisant showed statistically significant improvements in excessive daytime sleepiness compared to placebo, indicating its potential effectiveness [11][14]

Stocks rebounded from Wednesday's tech-led rout after an upbeat forecast from Micron helped put the brakes on a tech-driven selloff on a busy day for data and central bank meetings. As of 7:15am ET, S&P and Nasdaq  futures rose 0.6% following four down days. In premarket trading, Micron shares soared 11% after reporting blowout earnings. Europe’s Stoxx 600 index rose 0.2%, while Asian shares slid. The tech slide, combined with dovish comments from a Federal Reserve official, helped boost Treasuries. The yie ...

Core Company Overview - Core Natural Resources, Inc. (NYSE: CNR) is a leading producer of high-quality metallurgical and thermal coals, operating a portfolio of large-scale, low-cost longwall mines, including the Pennsylvania Mining Complex, Leer, Leer South, and West Elk mines [5] - The company was formed in January 2025 through the merger of CONSOL Energy and Arch Resources, and is headquartered in Canonsburg, Pennsylvania [5] Recent Operational Developments - Core has resumed longwall operations at its Leer South metallurgical mine in West Virginia, which had been idle since January 13, 2025, due to combustion-related activity [1] - The West Elk longwall mine in Colorado is now achieving consistent productivity levels after transitioning to the B-Seam, with expectations for continued improved performance [2] Management Commentary - The chairman and CEO of Core commended the operations team for prioritizing safety during the recovery and restart of the longwall system at Leer South, emphasizing the strategic importance of this asset [3] - The senior vice president and COO highlighted the professionalism and dedication of the operations team, projecting that Leer South will operate efficiently and effectively in 2026 [4] Financial Outlook - Core anticipates a significant improvement in financial performance in 2026 due to the restart at Leer South, improved geological conditions at West Elk, and substantial insurance recoveries related to the combustion event [4] - The company expects to benefit from the cessation of fire-suppression and idling costs at Leer South, as well as ongoing merger-related synergies [4]

Core Viewpoint - The shoemaker anticipates that tariffs will negatively impact profit margins and lead to a slowdown in revenue growth in the upcoming fiscal year [1] Group 1 - The company expects tariffs to weigh on its profit margins [1] - A slowdown in revenue growth is anticipated for the new fiscal year [1]

Playing catch-up in the anti-obesity business, Pfizer has bought global rights to an oral weight-loss drug from Fosun Pharma in another big licensing dealKey Takeaways:With the drug still at an early stage of development, Pfizer has negotiated an opt-out clause in case trials do not go to planFosun Pharma's revenues from innovative drugs jumped 18.09% in the first three quarters, emerging as a growth driver for the companyIt's becoming a familiar story: the Chinese drugs industry has signed another licensin ...

Chief Producer: Zhao Haijian Supervising Producer: Shi Shi Editor: Shi Shi Reporter: Gao Jianghong, Li Yinong （原标题：Hainan FTP in Action: China Opens Its Door Wider | SFC Markets and Finance） By Gao Jianghong, Yinong Li, SFC, 21st Century Business Herald On December 18, China's Hainan Free Trade Port officially launched island?wide special customs operations, creating a special customs supervision zone that links overseas markets with the Chinese mainland more smoothly under a "free first line, regulated sec ...

Core Viewpoint - LG Energy Solution Ltd (LGES) has had its battery supply contract with Ford Motor Company, valued at KRW 9.6 trillion (US$ 6.5 billion), canceled due to Ford's strategic shift in electric vehicle (EV) production and demand forecasts [1][2]. Group 1: Contract Cancellation - Ford has notified LGES of the cancellation of a contract for the supply of 109 gigawatt-hours (GWh) of nickel-cobalt-manganese (NCM) batteries, originally intended for Ford's light commercial vehicles (LCVs) from 2026 to 2032 [1]. - The cancellation is attributed to Ford's decision to discontinue certain EV models in response to recent policy changes and shifts in EV demand forecasts [2]. Group 2: Ford's Strategic Shift - Ford announced a US$ 19.5 billion one-off charge as part of its efforts to reshape its EV strategy, which includes pulling back from larger battery electric vehicle (BEV) models and focusing on hybrids and extended-range vehicles [2][3]. - The company aims to align its capital spending with customer demand and higher-return opportunities, targeting profitability for its Model e EV unit by 2029, with expected yearly improvements starting in 2026 [3]. Group 3: Leadership Statements - Ford's president and CEO, Jim Farley, emphasized that the changes are customer-driven, aimed at creating a stronger, more resilient, and profitable Ford [4]. - Farley noted that the operating reality has changed, prompting the redeployment of capital into higher-return growth opportunities [4].

Group 1 - The announcement indicates that no stabilisation was carried out for the securities offered by Zenita Maticmind SPA, as per the Market Abuse Regulation [2] - The total nominal amount of the securities issued by Zenita Maticmind SPA is €375,000,000, with an offer price set at 100 [3] - The stabilisation managers involved in this offering include BNP Paribas, JPM, Unicredit, CVC CM, Banca Akros, BPER, CACIB, DB, IMI, and Natixis [4] Group 2 - The securities mentioned in the announcement are not registered under the United States Securities Act of 1933 and cannot be offered or sold in the United States without proper registration or exemption [5]

Core Insights - As the new year approaches, individuals are encouraged to set financial goals, particularly focusing on enhancing retirement savings through appropriate account choices [1]. Group 1: Retirement Account Options - Many individuals appreciate the immediate tax benefits of traditional IRAs, while Roth IRAs offer tax-free growth and withdrawals in retirement [2][7]. - Choosing a Roth IRA may be advantageous for those in lower tax brackets, as they can benefit from tax-free withdrawals later when they may be in higher tax brackets [3][4]. - Concerns about future tax rate increases make Roth IRAs appealing, as they allow individuals to lock in their current tax rate, ensuring tax-free withdrawals regardless of future tax changes [5][6]. Group 2: Flexibility in Retirement Savings - Roth IRAs provide greater flexibility for future withdrawals, accommodating potential changes in financial needs post-retirement [8].